Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials - Wikidata - wikimedia - TriplyDB

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

http://www.wikidata.org/entity/Q33619867

about

The impact of comorbidity on cancer and its treatment Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress Cardiac toxicity in cancer survivors Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Aneugenic effects of epirubicin in somatic and germinal cells of male mice Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Cardiac risk in the treatment of breast cancer: assessment and management.Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells Cancer drug related cardiotoxicity during breast cancer treatment.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Management of chemotherapy induced cardiomyopathy.Cardiac tumors.Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.The minipig as a new model for the evaluation of doxorubicin-induced chronic toxicity.Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Cardio-oncology: what you need to know now for clinical practice and echocardiography.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Long-term risk of medical conditions associated with breast cancer treatment 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.Nuclear imaging in detection and monitoring of cardiotoxicity.Cancer, physical activity, and exercise Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy Navigator channel adaptation to reconstruct three dimensional heart volumes from two dimensional radiotherapy planning data.Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Chemotherapy-induced cardiotoxicity.Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.Paeoniflorin protects myocardial cell from doxorubicin-induced apoptosis through inhibition of NADPH oxidase.

P2860

Q26764935-B8005A6A-F09E-4DE3-B245-5700D76C3FFB Q26780547-67E19626-AC48-4139-B152-2810BFF4B2EC Q26851957-162C5CB7-4DF7-4AED-9D06-DFF102D6EF3B Q26859193-45698519-6D0D-4585-BF8D-8F208943B4A3 Q26991817-39B6C646-141F-4FD1-B17D-DBF86995E191 Q26999300-AC3D727B-1ECE-469F-A781-D7F0E2B2D5F5 Q27007849-58F17A54-0598-4485-8CDC-AD92CD12F009 Q27010466-52346EE9-EA7B-4BCD-9EFA-19193BECD839 Q27027354-7774DBE1-B95E-41F8-AF42-11534D061C48 Q27336080-14A67825-EDD1-438C-9C94-E7D8760C34A4 Q28068290-831FE7B4-1C80-42F8-872D-8B1272699F61 Q28070311-11022333-B99E-4C7B-87A0-D11AAE4CD92B Q28081385-85350219-7F62-444B-A687-43A32C3513A4 Q28084683-0390488D-2E9F-4A12-9A79-BC716AA9B28F Q28247479-71677300-5BAA-4C34-852A-09FDAC6D40C6 Q28291499-2637758C-1267-4B31-839E-B6B3E83866A6 Q28487998-B15A59E5-E974-495A-9329-665C1989E518 Q28553631-CACE4B17-3274-430C-B625-324D9693A73A Q28554422-D7EE4F3A-8F89-4959-A614-385EEBD6F554 Q30251498-08A4DB2E-460E-4745-8ED4-2AD7FA132223 Q30399577-AC0978D4-ED14-462C-A5BB-69A6E3E351E7 Q30461441-CD692850-5E97-41C9-8D93-0324DC9E7548 Q30472884-3C918E58-C003-4997-AF9F-EC5A93009820 Q33404672-186CF98D-70EF-4466-A51A-9A5C3906D2E4 Q33418655-3BBEF70E-A3D3-41E6-B379-B9091E76BEB3 Q33427938-3114E683-17BC-49AE-BA5B-C746FFF9342A Q33671281-5C59147F-ABDB-4ADF-8649-2F65D400E35D Q33701308-C854A6BA-9C5F-4CC1-9541-EA27323736EE Q33824842-4C42D440-F3B6-47E2-B31B-75C573C51E82 Q33895877-EAE854D3-4102-418F-9C25-E3CD215C084D Q33900003-5EB6CEB4-F756-4035-A072-36B1C47F8592 Q33913561-7F9FF692-20EF-4FED-B714-824B06878B5F Q33942611-2814531D-567B-4BA3-A315-D8E3C3C2C7F8 Q34004946-F15A6684-BA64-400D-B293-9FCA9DAB6DEA Q34110096-619CE973-A73A-43A0-8CA2-412740A34690 Q34132543-6DCFB02D-E1EA-453D-8447-18A41BC4F3B9 Q34184798-DAF5C0F4-18A4-41EA-B7DB-142BEE51B5EB Q34258080-A8EFCA7D-531C-4A3D-9430-DCA3A0A10E6D Q34333236-EDBEBBCA-F52B-45C1-A634-64830403C239 Q34501069-713818AF-476F-44C5-B0C4-152BE1D7791B

P2860

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

http://www.wikidata.org/entity/Q33619867

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@ast

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@en

type

label

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@ast

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@en

prefLabel

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@ast

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@en

P1433

Q33619867-CB89BA82-892B-4B40-8F5F-BEF87DC9E762

P1476

Q33619867-04A7C579-44CC-41C7-8CA4-758FB5CEE473

P2093

Q33619867-036FD0A6-3B60-4454-A9D8-18B44A6AEFB1

Q33619867-295F1216-0C6B-417C-959B-0AA54614310E

Q33619867-72268DEF-F464-4D22-B354-2E74A46945F1

Q33619867-800EF21B-E648-4B9E-AB76-966250DA8EF3

Q33619867-E1628A8B-3188-4788-96DB-B54829CF5CEF

Q33619867-FB3D8AE6-31C0-4C7B-90CE-C8E1FC403088

P275

Q33619867-0DAB6C3E-FAFA-4314-9A4E-A6F8DE6831B0

P2860

Q33619867-046EC26F-506F-486A-B2BF-557656A35F72

Q33619867-07719B9B-34C5-4E9E-AF2E-80F6D794CF1B

Q33619867-086AACEC-283A-4196-B401-1C6878F95725

Q33619867-0EA39442-0DF9-4A16-AB0D-230268B7418E

Q33619867-1024953C-3ACA-48D8-AA92-EF139F8A5C20

Q33619867-1391BD79-E946-408F-AF73-9405D0A19857

Q33619867-13C0FB7A-1561-4D81-AC41-D6933D19CE3D

Q33619867-15F4C8A0-2EC4-4AA7-92FD-52460A1F9CDB

Q33619867-1A08A556-A8FD-4D2E-B141-1741F2487311

Q33619867-1D5137DE-BA4F-4251-BBA7-DCFF092D9C1F

P2888

Q33619867-2B39CE34-4E36-4B40-BB97-7A753C7536A6

P304

Q33619867-F0FA1D05-382B-4CB3-948B-212800F513EB

P31

Q33619867-1E5F29BA-20F2-4632-A41E-549030A158A8

P356

Q33619867-31C807D6-8691-45BB-9738-513483F1690B

P407

Q33619867-59E4B95F-7BD1-414B-B276-48F10BCE6572

P478

Q33619867-FE1E591F-CFF2-4C11-BC15-27B02BCB3DFF

P50

Q33619867-94313E1C-9E75-4524-BDE1-8AF8D711C5A5

P5008

Q33619867-548E3B2A-04F0-4042-B843-D1F7AF0E6403

P577

Q33619867-4E7E95EE-3040-491F-BC19-29BCB718C57B

P5875

Q33619867-E64A420E-F8DB-4270-8488-B5C5A0EBCE5B

P6179

Q33619867-045DB9E8-38AD-46D8-A251-1CBA3D7C4DE3

P698

Q33619867-D87EB6E3-DA7E-43DC-AC1B-421CAE8EFED0

P921

Q33619867-2174CC5F-2DD2-4826-B268-F896842366E0

Q33619867-32C65E22-5192-49E1-9C36-020FCBB58BF2

Q33619867-7328C102-0C37-4295-A567-991FE13E8BE8

Q33619867-E25958DA-1E9A-492E-8DD9-C16BF8BFC45F

Q33619867-E784D94A-964D-4CFE-A162-B152BD7DE95D

Q33619867-EF2B8058-98D8-41F3-A8D6-FCD8E72E2666

P932

Q33619867-7A6B8812-833F-4CAD-9A5D-9BFB565E14F6

P356

1471-2407-10-337

P1433

P1476

Cardiotoxicity of anthracyclin ...... f randomised controlled trials

@en

P2093

Alison Jones

http://www.w3.org/2001/XMLSchema#string

Christopher J Plummer

http://www.w3.org/2001/XMLSchema#string

Gill Levitt

http://www.w3.org/2001/XMLSchema#string

Lesley A Smith

http://www.w3.org/2001/XMLSchema#string

Mark Verrill

http://www.w3.org/2001/XMLSchema#string

Peter Canney

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

Cardioprotective interventions for cancer patients receiving anthracyclines

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors

Risk factors for doxorubicin-induced congestive heart failure

P2888

1471-2407-10-337

P304

337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-337

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Victoria Cornelius

P5008

P577

2010-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44851040

http://www.w3.org/2001/XMLSchema#string

P6179

1025505974

http://www.w3.org/2001/XMLSchema#string

P698

20587042

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

polycyclic compound

P932

2907344

http://www.w3.org/2001/XMLSchema#string